Incanthera (AQSE:INC) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Incanthera Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

AQSE:INC vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Incanthera's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incanthera Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incanthera's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Incanthera's Short Percentage of Float falls into.


Incanthera Business Description

Address C/o Gateley Plc, 98 King Street, Manchester, GBR, M2 4WU
Incanthera PLC is clinical stage drug development. It specializes in dermatology and oncology therapeutics. The company has launched a skincare range called Skin + CELL, which addresses and enhances life quality through effective delivery of bioactive ingredients capable of energising the skin's natural repair and defence processes at the cellular level. It has one reportable segment, namely the development of dermatology and pharmaceutical products, within the United Kingdom and Switzerland.